• image

    the Phase 3 trial DIAGNODE-3

    and other ongoing trials

    Read More
  • image

    Developing precision therapies

    for type 1 diabetes

    VIDEO
  • image

    Intralymphatic immunotherapy

    with Diamyd®

    VIDEO

Anmälan om deltagande vid extra bolagsstämma

Aktieägarna i Diamyd Medical AB (publ) kallas härmed till extra bolagsstämma måndagen den 26 juni 2023 kl.10:00.

 

Till Anmälan

Press Releases

  June 1, 2023

Events & Mediawatch

 June 1, 2023   Sweden

Company Presentation

 April 13, 2023
Download PDF

Thanks to JDRF's very large network, strong brand and financial support, the collaboration significantly strengthens our preparations for market and further accelerates patient recruitment for the Phase 3 trial DIAGNODE-3.

Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly Report 2 22/23

Calendar

 Dates for financial information and other events
June 2 − June 8, 2023
BIO International Convention
June 13, 2023
Aktiespararnas Småbolagsdagar
June 23 − June 26, 2023
ADA 83rd Scientific Sessions
June 26, 2023
Extra General Meeting
June 28, 2023
Quarterly Report III
Quarterly Report 3 2022/2023
October 11, 2023
Year-end report
Year-end report 2022/2023

THE COMPANY

Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)


Read More

Order GAD for preclinical research

ORDER

Annual Report

  November 29, 2022
Annual Report cover image
Download

Contact Us

Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm
Visiting addresses:
Kungsgatan 29, SE-111 56 Stockholm
+46 8 661 00 26
Umeå:
Formvägen 7B, SE-906 21 Umeå

Subscribe

   

Follow Us

  ©
GAD PRODUCTS
Order GAD for preclinical research